Effects of topiramate on neurophysiological and neuropsychological tests in migraine patients

Journal of Clinical Neuroscience

Volumn 16, Issue 12, 2009, Pages 1588-1591

  Kececi, Hulusi ^a   Atakay, Selcuk ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

ERP; Migraine; P300; Topiramate

Indexed keywords

ACETYLSALICYLIC ACID; ERGOT DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TOPIRAMATE; TRIPTAN DERIVATIVE;

ADULT; AMPLITUDE MODULATION; ANOREXIA; ARTICLE; ATAXIA; BLURRED VISION; CLINICAL ARTICLE; COGNITIVE DEFECT; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; EVOKED CORTICAL RESPONSE; FATIGUE; FEMALE; FREQUENCY ANALYSIS; HUMAN; HYPOTENSION; IRRITABILITY; LATENT PERIOD; MALE; MEMORY DISORDER; MENSTRUATION DISORDER; MIGRAINE; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; SYNCOPE; TASTE DISORDER; VERTIGO; VISUAL ANALOG SCALE; WECHSLER MEMORY SCALE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTICONVULSANTS; CEREBRAL CORTEX; EVENT-RELATED POTENTIALS, P300; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; MALE; MEMORY; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; REACTION TIME; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70449525576     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.03.025     Document Type: Article

References (31)

1. Lipton R.B., Bigal M.E., Diamond M., et al. AMPP advisory group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68 (2007) 343-349
2. Kececi H., and Dener S. Epidemiological and clinical characteristics of migraine in Sivas, Turkey. Headache 42 (2002) 275-280
3. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Eng J Med 346 (2002) 257-270
4. Silberstein S.D. Practice parameters: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standard subcommittee of the American academy of neurology. Neurology 55 (2000) 754-762
5. Langtry H.D., Gillis J.C., and Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54 (1997) 752-773
6. Shank R.P., Gardocki J.F., Streeter A.J., et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41 Suppl. 1 (2000) S3-S9
7. Coulter D.A., Sombati S., and DeLorenzo R.J. Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons. Epilepsia 36 Suppl. 3 (1995) S40
8. Gibbs JW I.I.I., Sombati S., DeLorenzo R.J., et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41 Suppl. 1 (2000) S10-S16
9. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28 (1997) 167-179
10. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41 Suppl. 1 (2000) S17-S20
11. Dodgson S.J., Shank R.P., and Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 Suppl. 1 (2000) S35-S39
12. Silberstein S.D. Topiramate in migraine prevention. Expert Rev Neurotherapeutics 3 (2003) 761-771
13. Silberstein S.D., Neto W., and Schmitt J. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61 (2004) 490-495
14. Brandes J.L., Saper J.R., Diamond M., et al. Topiramate for migraine prevention - a randomized controlled trial. JAMA 291 (2004) 965-973
15. Diener H.C., Tfelt-Hansen P., Dahlöf C., et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 251 (2004) 943-950
16. Ben-Menachem E., Henriksen O., Dam M., et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37 (1996) 539-543
17. Faught E., Wilder B.J., Ramsay R.E., et al. Topiramate placebo controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 46 (1996) 1684-1690
18. Privitera M., Fincham R., Penry J., et al. Topiramate placebo controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 46 (1996) 1678-1683
19. Rosenfeld W., Abou-Khalil B., Reife R., et al. Topiramate YF/YG study group. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy. Epilepsia 37 Suppl. 5 (1996) 153
20. Sharief M., Viteri C., Ben-Menachem E., et al. Double-blind, placebo controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25 (1996) 217-224
21. Tassinari C.A., Michelucci R., Chauvel P., et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 37 (1996) 763-768
22. International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia 2004;24(Suppl. 1):1-160.
23. Thompson P.J., Baxendale S.A., Duncan J.S., et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69 (2000) 636-641
24. Groselj J., Guerrini R., Van Oene J., et al. Experience with topiramate monotherapy in elderly patients with recent onset epilepsy. Acta Neurol Scand 112 (2005) 144-150
25. Blum D., Meador K., Biton V., et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67 (2006) 400-406
26. Aldenkamp A., Baker G., Mulder O., et al. A multicenter randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial onset seizures. Epilepsia 41 (2000) 1167-1178
27. Burton L.A., and Harden C. Effect of topiramate on attention. Epilepsy Res 27 (1997) 29-32
28. Diamond M., Dahlof C., Papadopoulos G., et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache 45 (2005) 1023-1030
29. Bussone G., Diener H.C., Pfeil J., et al. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59 (2005) 961-968
30. Shaygannejad V., Janghorbani M., Ghorbani A., et al. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 46 (2006) 642-648
31. Smith M.E., Gevins A., McEvoy L.K., et al. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia 47 (2006) 695-703